CS
STRO icon

Candriam SCA’s Sutro Biopharma STRO Stock Holding History

Candriam SCA’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,042
Closed -$2.49M – 725
2024
Q1 		$2.49M Sell
44,042
-45,781
-51% -$2.02M 0.02% 472
2023
Q4 		$3.85M Sell
89,823
-64,000
-42% -$2.03M 0.03% 373
2023
Q3 		$5.34M Sell
153,823
-9,000
-6% -$392K 0.04% 301
2023
Q2 		$7.57M Sell
162,823
-23,255
-12% -$1.16M 0.05% 283
2023
Q1 		$7.91M Buy
186,078
+107,160
+136% +$6.8M 0.05% 292
2022
Q4 		$6.38M Sell
78,918
-100,966
-56% -$7.02M 0.04% 342
2022
Q3 		$9.98M Buy
179,884
+173,623
+2,773% +$10.3M 0.07% 273
2022
Q2 		$326K Buy
+6,261
New +$350K ﹤0.01% 755
2021
Q3 		– Sell
-36,621
Closed -$6.81M – 907
2021
Q2 		$6.81M Sell
36,621
-190
-0.5% -$37.2K 0.05% 346
2021
Q1 		$7.68M Hold
36,811
– – 0.06% 299
2020
Q4 		$7.99M Buy
+36,811
New +$6.09M 0.06% 307

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Candriam SCA's STRO Position: Q2 2024 in Review

Candriam SCA sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 44,042 shares — an estimated $2.49M sold.

Candriam SCA first reported a position in STRO in Q4 2020 and held it in 11 quarters. The position peaked at $9.98M in Q3 2022. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Candriam SCA reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 44,042 Sutro Biopharma shares in Q2 2024, an estimated $2.49M.
  • Candriam SCA first reported a position in Sutro Biopharma in Q4 2020 and held it in 11 quarters.
  • Candriam SCA's Sutro Biopharma position peaked at $9.98M in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.